Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

NCT05054725 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT05054725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05054725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2021
Completion date
August 29, 2024
Enrollment
47 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer